| Literature DB >> 29686709 |
Márcia Aires Rodrigues de Freitas1,2, Alice Vieira da Costa2, Luciana Alves de Medeiros2, Mario da Silva Garrote Filho2, Angélica Lemos Debs Diniz1, Nilson Penha-Silva2.
Abstract
Preeclampsia (PE) is classified as early-onset PE (EOPE) and late-onset PE (LOPE) when present before or after 34 weeks of gestation, respectively. This transversal study aimed to investigate the differences and possible associations existing in the anthropometric, hemodynamic, hematologic, and biochemical profiles of late- and early-onset preeclampsia. The study included 65 volunteers admitted to a tertiary hospital in Brazil: 29 normotensive and 36 with preeclampsia (13 with EOPE and 23 with LOPE). Pregnant women with LOPE presented greater weight gain and borderline increase in body mass index at the end of gestation in relation to the other groups, which is compatible with the metabolic origin, associated with obesity, attributed to this form of the disease. Pregnant women with EOPE presented a borderline reduction in the number of erythrocytes and a significant decrease in the number of platelets, in addition to a significant increase in reticulocytes, serum iron, and ferritin when compared to normotensive pregnant women and pregnant women with LOPE. A significant increase in osmotic stability of erythrocytes was observed in the EOPE group in relation to other groups. Hemodynamic analysis by Doppler ultrasonography of the ophthalmic artery showed that both groups of pregnant women with PE presented alterations compatible with the occurrence of hyperflow in the orbital territory. These hemodynamic changes were associated with changes in hematimetric indices.Entities:
Year: 2018 PMID: 29686709 PMCID: PMC5852893 DOI: 10.1155/2018/9628726
Source DB: PubMed Journal: Obstet Gynecol Int ISSN: 1687-9597
Figure 1Typical curve of osmotic stability of erythrocytes. The lower plateau defines the Amin variable, which represents the amount of basal hemolysis present in the blood sample of each study volunteer. The decrease in the tonicity of the medium is associated with increased lysis of erythrocytes and release of hemoglobin in the solution, resulting in increased absorbance at 540 nm with formation of a curve of sigmoidal nature whose upper plateau defines the Amax variable, which represents the occurrence of 100% hemolysis. The curve passes through an intermediate point defining the H50 variable, which represents the concentration of NaCl required to promote 50% hemolysis. The saline concentration at the starting point of the curve defines the H0 variable, which is the saline concentration required to initiate in vitro hemolysis and which can be calculated by the formula H0 = H50 + 4 dX/2. The saline concentration at the point where the in vitro lysis reaches its maximum plateau defines the H100 variable, which represents the saline concentration necessary to promote the total lysis of the red blood cells, being calculated by the formula H100 = H50 − 4 dX/2. The dX variable represents a quarter of the variation in saline concentration required to promote 100% hemolysis.
Figure 2Doppler velocimetry of ophthalmic artery (OA), with identification of the pulse wave velocity (PWV) of the OA. The X-axis represents the time (seconds), and the Y-axis represents the flow velocity (cm/s). A rapid increase in velocity is observed, with a peak systolic velocity (PSV), followed by a rapid fall, and a new velocity rise with the formation of a second rounded systolic peak (P2), followed by the aortic notch, which closes the systolic cycle. Then, there is an increase in velocity with formation of the diastolic phase of the PWV, which ends with the end-diastolic velocity (EDV). The P2/PSV ratio is referred to as peak ratio [17].
Figure 3Representation of Doppler velocimetry of ophthalmic artery in a normotensive volunteer (PR = 0.56; P2 = 24.25) (a) and in volunteers with late-onset preeclampsia (LOPE: PR = 0.78; P2 = 25.24) (b) and early-onset preeclampsia (EOPE: PR = 0.93; P2 = 35.23) (c). PR is the P2/PSV ratio, and P2 is the second peak systolic velocity.
Comparisons of the values of variables from normotensive pregnant women and pregnant women with late-onset preeclampsia (LOPE) and early-onset preeclampsia (EOPE) at the third trimester of pregnancy.
| Variables | Normotensive | LOPE | EOPE |
|---|---|---|---|
| Maternal age (y)† | 25.0 ± 10.5 (28) | 26.0 ± 14.0 (23) | 27.0 ± 10.0 (13) |
| Weight gain (kg)§ | 10.0 ± 3.0 (26)a | 20.0 ± 7.0 (9)a,b | 14.0 ± 5.0 (5)b |
| BMI (pregestational) (kg/m2)§ | 24.2 ± 5.3 (27) | 25.16 ± 10.3 (10) | 23.3 ± 5.5 (7) |
| BMI (kg/m2)§ | 29.2 ± 5.1 (27)a | 32.0 ± 8.4 (13)a | 29.7 ± 6.2 (6) |
| Gestational age (w)§ | 40.0 ± 1.0 (29)a,b | 38.0 ± 2.0 (20)b,c | 31.5 ± 4.0 (13)a,c |
| Birth weight (kg)§ | 3.5 ± 0.5 (28)a,b | 2.9 ± 0.6 (22)b,c | 1.8 ± 0.9 (11)a,c |
| Growth centile (%) | |||
| <10∗ | 0% (0) | 4.3% (1) | 23.1% (3) |
| 10–50∗ | 21.0% (6) | 39.1% (9) | 38.5% (5) |
| 50–90∗ | 65.5% (19) | 39.1% (9) | 7.7% (1) |
| >90∗ | 10.3% (3) | 4.3% (1) | 15.4% (2) |
| Unknown | 3.4% (1) | 13.0% (3) | 15.4% (2) |
| Placenta weight (g)§ | 590.0 ± 80.0 (28)a | 512.5 ± 160.0 (22)b | 337.5 ± 200.0 (12)a,b |
| SBP (mmHg)§ | 120.0 ± 10.0 (28)a,b | 150.0 ± 30.0 (23)a | 150.0 ± 20.0 (13)b |
| DBP (mmHg)§ | 70.0 ± 10.0 (28)a,b | 100 ± 20.0 (23)a | 100.0 ± 10.0 (13)b |
| RBC (106 cells/mm3)† | 4.15 ± 0.57 (29)a | 4.08 ± 0.44 (22) | 3.78 ± 0.68 (13)a |
| Ht (%)† | 34.6 ± 3.8 (29) | 34.7 ± 5.6 (22) | 33.2 ± 3.8 (13) |
| Hb (g/dL)† | 12.0 ± 1.5 (29) | 11.8 ± 1.8 (22) | 11.3 ± 1.3 (13) |
| MCV (fL)§ | 85.3 ± 6.4 (29) | 82.9 ± 8.9 (21) | 87.3 ± 6.1 (13) |
| MCH (pg)§ | 29.5 ± 2.7 (29) | 27.9 ± 3.7 (21) | 29.8 ± 2.7 (13) |
| MCHC (g/dL)§ | 34.1 ± 1.6 (29) | 33.8 ± 1.5 (21) | 33.9 ± 2.3 (13) |
| RDW (%)§ | 13.3 ± 1.3 (29) | 14.0 ± 1.9 (21) | 13.0 ± 1.3 (13) |
| Rtc index (%)§ | 1.1 ± 1.4 (27)a | 1.4 ± 1.1 (21) | 1.7 ± 1.6 (11)a |
| Plt (103 cells/mm3)§ | 229.0 ± 7.0 (29)a | 213.5 ± 102 (22)b | 141.0 ± 52.0 (13)a,b |
| MPV (fL)§ | 11.0 ± 2.0 (29) | 10.2 ± 2.4 (21) | 10.0 ± 2.3 (13) |
| t-C (mg/dL)§ | 219.2 ± 65.0 (27) | 198.0 ± 59.0 (19) | 227.0 ± 61.9 (12) |
| HDL-C (mg/dL)§ | 59.8 ± 28 (27) | 59.9 ± 13.3 (21) | 60.3 ± 20.5 (12) |
| VLDL-C (mg/dL)§ | 40.0 ± 16.0 (28) | 40.5 ± 19.8 (16) | 47.0 ± 31.2 (11) |
| LDL-C (mg/dL)§ | 131.5 ± 63.3 (28) | 106.0 ± 54.0 (17) | 113.5 ± 66.3 (11) |
| TGC (mg/dL)§ | 203.0 ± 111.0 (28) | 210.0 ± 128.0 (17) | 238.0 ± 121.8 (12) |
| Proteinuria (0+)∗ | 100.0% (29)a,b | 31.3% (5)a | 0% (0)b |
| Proteinuria (1+)∗ | 0% (0) | 18.8% (3) | 22.2% (2) |
| Proteinuria (2+)∗ | 0% (0) | 37.5% (6) | 44.4% (4) |
| Proteinuria (3+)∗ | 0% (0) | 12.5% (2) | 11.1% (1) |
| Proteinuria (4+)∗ | 0% (0) | 0% (0) | 22.2% (2) |
| Proteinuria (unknown) | 0% (0) | 30.4% (7) | 30.7% (4) |
| ALT (U/L)§ | 14.9 ± 2.9 (29)a,b | 17.0 ± 11.0 (23)a | 27.0 ± 27.7 (13)b |
| AST (U/L)§ | 9.0 ± 3.2 (28)a,b | 12.0 ± 7.0 (23)a | 22.0 ± 45.8 (13)b |
| LDH (U/L)§ | 193.0 ± 39.0 (27)a,b | 236.0 ± 49.0 (23)a,c | 292.0 ± 274.0 (13)b,c |
| HSA (g/dL)§ | 3.5 ± 0.4 (25)a | 3.3 ± 0.6 (15)b | 3.0 ± 0.6 (11)a,b |
| Urea (mg/dL)† | 14.6 ± 3.6 (29)a,b | 21.0 ± 10.9 (23)a,c | 35.0 ± 19.0 (13)b,c |
| Cn (mg/dL)§ | 0.58 ± 0.21 (29)a | 0.70 ± 0.2 (23) | 0.78 ± 0.29 (12)a |
| Uric acid (mg/dL)§ | 4.3 ± 1.0 (29)a,b | 5.4 ± 1.4 (23)a,c | 7.6 ± 1.4 (13)b,c |
| i-B (mg/dL)§ | 0.205 ± 0.13 (26) | 0.17 ± 0.23 (16) | 0.220 ± 0.480 (11) |
| t-B (mg/dL)§ | 0.425 ± 0.19 (26) | 0.28 ± 0.17 (20) | 0.340 ± 0.490 (13) |
| Na (mEq/L)§ | 138.0 ± 2.5 (24)a | 140.0 ± 4.0 (17)c | 136.0 ± 5.0 (13)a,c |
| K (mEq/L)§ | 4.05 ± 0.42 (25)a | 4.0 ± 0.5 (17) | 4.56 ± 0.47 (13)a |
| Fe (mg/dL)† | 78.0 ± 46.0 (27)a | 84.9 ± 46.1 (20)b | 106.5 ± 89.3 (12)a,b |
| Ferritin (ng/mL)§ | 26.5 ± 14.64 (25)a | 31.5 ± 32.5 (17)b | 156.2 ± 244.7 (12)a,b |
| RI§ | 0.78 ± 0.04 (26)a,b | 0.73 ± 0.09 (17)a | 0.63 ± 0.08 (10)b |
| PI§ | 1.96 ± 0.44 (26)a,b | 1.62 ± 0.46 (17)a | 1.14 ± 0.87 (10)b |
| PSV (cm/seg)§ | 31.4 ± 7.4 (27) | 30.6 ± 9.8 (17) | 30.0 ± 15.0 (10) |
| P2 (cm/seg)§ | 17.9 ± 10.7 (27)a | 22.3 ± 4.1 (17) | 25.3 ± 14.2 (10)a |
| PR§ | 0.58 ± 0.13 (27)a,b | 0.71 ± 0.27 (17)a | 0.85 ± 0.19 (10)b |
|
| 12.5 ± 4.9 (26) | 13.3 ± 4.8 (15) | 16.2 ± 7.1 (7) |
| EDV (cm/seg)§ | 7.1 ± 3.7 (27) | 8.2 ± 3.2 (17) | 10.8 ± 5.4 (9) |
|
| 1.060 ± 0.148 (26) | 1.032 ± 0.237 (22) | 0.099 ± 0.074 (11) |
|
| 0.019 ± 0.021 (26) | 0.019 ± 0.032 (22) | 0.009 ± 0.009 (11) |
|
| 0.480 ± 0.031 (26)d | 0.472 ± 0.048 (22) | 0.458 ± 0.028 (11)d |
|
| 0.447 ± 0.036 (26)a | 0.437 ± 0.037 (22)d | 0.417 ± 0.028 (11)a,d |
|
| 0.423 ± 0.030 (26)a | 0.402 ± 0.034 (22)d | 0.388 ± 0.013 (11)a,d |
| 1/ | 2.236 ± 0.177 (26)a | 2.283 ± 0.201 (22)d | 2.400 ± 0.161 (11)a,d |
|
| 0.447 ± 0.036 (26)a | 0.437 ± 0.037 (22)d | 0.417 ± 0.028 (11)a,d |
|
| 0.017 ± 0.027 (26) | 0.015 ± 0.007 (22) | 0.016 ± 0.010 (11) |
|
| 0.038 ± 0.208 (26) | 0.035 ± 0.018 (22) | 0.038 ± 0.022 (11) |
|
| 0.016 ± 0.007 (26) | 0.014 ± 0.011 (22) | 0.018 ± 0.011 (11) |
The values are presented as ∗frequency, §median ± IQR (N), or †mean ± SD (N). a,b,c,dStatistically significant (p < 0.05) and borderline differences (0.05 < p < 0.10), respectively, when present as pairs of common letters. Comparisons were done by chi-square test for ∗categorical data, Kruskal–Wallis with Dunn–Bonferroni post hoc test for §nonnormally distributed data, or ANOVA with Bonferroni post hoc test for †normally distributed data. SBP, systolic blood pressure; DBP, diastolic blood pressure; Ht, hematocrit; Hb, hemoglobin; RBC, erythrocytes; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW, red-cell distribution width; Rtc index, reticulocyte index; Plt, platelets; MPV, mean platelet volume; t-C, total cholesterol; HDL-C, high-density lipoprotein cholesterol; VLDL-C, very-low-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TGC, triglycerides; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; HSA, human serum albumin; Cn, creatinine; i-B, indirect bilirubin; t-B, total bilirubin; Na+, sodium; K+, potassium; Fe, serum iron; RI, resistance index; PI, pulsatility index; PSV, peak systolic velocity; P2, second peak of systolic velocity; PR, peak ratio; Vmean, mean velocity; EDV, end-diastolic velocity; Amin, absorbance at 540 nm associated with residual lysis of the erythrocytes population; Amax, absorbance at 540 nm associated with lysis of the whole population of erythrocytes; H0, saline concentration where in vitro hemolysis begins; H50, saline concentration capable of promoting 50% hemolysis, H100, saline concentration where in vitro lysis ends; 1/H50, inverse NaCl concentration capable of promoting 50% hemolysis; dX, variation in the concentration of NaCl responsible for total hemolysis.
Figure 4Mechanical selection and increased osmotic stability of erythrocytes in preeclampsia.